Overview

Evaluate Bioequivalence of Burotam (1/1 g/Vial)

Status:
Active, not recruiting

Trial end date:
2023-02-20

Target enrollment:

Participant gender:

Summary

A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of cefoperazone sodium and sulbactam sodium combination (1/1 g/vial) after intravenous infusion of 1 g cefoperazone sodium and 1 g sulbactam sodium in healthy volunteers under fasting conditions

Phase:

Phase 4

Details

Lead Sponsor:

Yung Shin Pharm. Ind. Co., Ltd.

Treatments:

Cefoperazone
Sulbactam
Sulperazone